Lilly announces first Phase 1 data for sofetabart mipitecan in platinum-sensitive ovarian cancer

By Public Technologies
  • Eli Lilly will present oncology trial data at the ESMO Congress in Madrid, October 23-27, 2026.
  • Initial Phase 1 findings for sofetabart mipitecan with bevacizumab in platinum-sensitive ovarian cancer support its ongoing Phase 3 trial.
  • Updated first-line olomorasib findings in KRAS G12C-mutant lung cancer showed clinical activity and safety consistent with earlier results, supporting Phase 3 development.
  • Updated Phase 3 selpercatinib results in advanced RET-mutant medullary thyroid cancer build on data supporting global approvals.
  • Phase 3 postMONARCH survival data support switching endocrine therapy and CDK4/6 inhibitors following progression in advanced breast cancer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202610181805PR_NEWS_USPR_____DE73652) on October 18, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.